Edition:
United Kingdom

Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

72.90EUR
8:40am GMT
Change (% chg)

€-0.02 (-0.03%)
Prev Close
€72.92
Open
€72.76
Day's High
€73.03
Day's Low
€72.59
Volume
140,656
Avg. Vol
2,546,124
52-wk High
€80.44
52-wk Low
€62.88

Select another date:

Fri, Jan 18 2019

FDA advisory panel split over Sanofi-Lexicon diabetes drug

An advisory panel to the U.S. Food and Drug Administration was divided over whether to recommend approval of a treatment for type 1 diabetes developed by Lexicon Pharmaceuticals Inc and France's Sanofi SA.

UPDATE 2-FDA advisory panel split over Sanofi-Lexicon diabetes drug

Jan 17 An advisory panel to the U.S. Food and Drug Administration was divided over whether to recommend approval of a treatment for type 1 diabetes developed by Lexicon Pharmaceuticals Inc and France's Sanofi SA.

FDA advisory panel split over Sanofi-Lexicon diabetes drug

Jan 17 Independent experts on an FDA advisory panel were equally split when voting on whether to approve an oral treatment for type 1 diabetes developed by Lexicon Pharmaceuticals Inc and France's Sanofi SA.

U.S. top court rejects Amgen over cholesterol medication patent fight

WASHINGTON Amgen Inc on Monday lost its bid at the U.S. Supreme Court to overturn a ruling that kept the Regeneron Pharmaceuticals Inc and Sanofi SA cholesterol-lowering drug Praluent on the market, but the patent dispute among the rival drugmakers will continue in another trial.

UPDATE 4-U.S. top court rejects Amgen over cholesterol medication patent fight

WASHINGTON, Jan 7 Amgen Inc on Monday lost its bid at the U.S. Supreme Court to overturn a ruling that kept the Regeneron Pharmaceuticals Inc and Sanofi SA cholesterol-lowering drug Praluent on the market, but the patent dispute among the rival drugmakers will continue in another trial.

Sanofi to pay Regeneron $462 million in revised immuno-oncology deal

PARIS Sanofi will pay Regeneron some $462 million in a revision of their deal in immuno-oncology, a growing sector in healthcare research which aims to help the body's own immune system fight cancer.

CORRECTED-UPDATE 1-Sanofi to pay Regeneron $462 mln in revised immuno-oncology deal

PARIS, Jan 7 Sanofi will pay Regeneron some $462 million in a revision of their deal in immuno-oncology, a growing sector in healthcare research which aims to help the body's own immune system fight cancer.

Drugmakers Sanofi, Regeneron restructure immuno-oncology deal

PARIS, Jan 7 Healthcare companies Sanofi and Regeneron have restructured an earlier deal in the immuno-oncology sector, which will result in Sanofi paying its U.S. partner some $582 million.

Sanofi to invest 80 mln euros in German biotech group BioNTech

FRANKFURT, Jan 4 French drugmaker Sanofi will invest 80 million euros ($90.9 million) in BioNTech and expand its collaboration with the German biotech group, BioNTech said on Friday.

Sanofi's pediatric hexavalent vaccine approved by U.S. FDA

PARIS The U.S. Food and Drug Administration approved Sanofi's new pediatric vaccine immunizing children against six diseases, the French pharmaceutical lab said on Wednesday.

Select another date: